- Home
- PLSE vs ELVN Comparison
PLSE vs ELVN Comparison
Compare PLSE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | ELVN |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLSE | ELVN |
|---|---|---|
| Price | $14.09 | $17.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $22.00 | ★ $41.20 |
| AVG Volume (30 Days) | 183.4K | ★ 661.3K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $86,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,002.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $13.30 |
| 52 Week High | $25.00 | $25.37 |
Technical Indicators
Market Signals| Indicator | PLSE | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 35.75 |
| Support Level | $13.12 | $16.62 |
| Resistance Level | $14.75 | $20.47 |
| Average True Range (ATR) | 0.61 | 1.31 |
| MACD | 0.22 | -0.48 |
| Stochastic Oscillator | 58.33 | 11.68 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.